MUMBAI: India’s leading drug companies got clean chit regarding manufacturing in 10 days by the US Food and Drug Administration (USFDA). The decision comes at a time when supply-chain has been decreased due to the Covid-19 pandemic are causing drug shortages across the world.
Earlier on Monday, Lupin Limited, the third largest generic drug supplier in the US by prescriptions, and Dr Reddy’s Laboratories received establishment inspection reports (EIRs), indicating closure of investigation by the US drug regulator of their manufacturing plants. Lupin’s also received EIR facility in Central India’s Nagpur.
“We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility,” Lupin managing director Nilesh Gupta said.
The company got the EIR for its active pharmaceutical plant 5 at Miryalaguda in Telangana, said Hyderabad-based Dr Reddy in a statement.
